Partnering with informed patients is a central tenant of the newly released joint 2012 Guidelines For Diagnosis and Management of Patients with Stable Ischemic Disease, as well as SCAI’s consensus update on Ad-Hoc PCI. And new studies about angioplasty and stents are being presented regularly that call for shared decision-making: for example, the OVER study, showing that endovascular repair of abdominal aortic aneurysms with stent grafts is equivalent to open surgery, the FREEDOM study discussing the options for multivessel disease in diabetic patients, and FAME 2 for the treatment of stable heart disease with significant ischemia as measured by fractional flow reserve. Patient preference comes into play in all of these. Continue reading
Category Archives: Patients
The Activated Patient Blog Launches
Fractional Flow (Chart) Reserve
Click to enlarge flow chart
Best medical practices for angioplasty and stent placement are a moving target because no sooner than a guideline is published it can be changed by the results of a more recent study. And the SCAI Ad Hoc PCI Consensus Statement posted online just three days ago is no exception. Continue reading
Filed under FAME I / FAME II, FFR, Non-Invasive Testing, Optimal Medical Therapy
Ad Hoc Angioplasty: The Patient Is On The Table
Cardiologist talks to a patient “on the table” in cath lab
Something that is “on the table” is defined as an item that is “up for discussion.” And this week The Society for Cardiac Angiography and Interventions (SCAI) issued a consensus statement about the proper use of “ad hoc PCI” — and the patient was definitely on the table, up for discussion, part of the conversation.
Since we’re into definitions, ad hoc PCI is the scenario in which a diagnostic catheterization is followed in the same session by PCI (angioplasty and stents). And this is a common scenario: in New York State, for example, 80% of all angioplasties are done in the same session as the diagnostic angiogram, although the vast majority of these are emergency or primary angioplasties, where a patient in the midst of a heart attack (or close to it) is brought into the cath lab and the blockage is opened up, saving the heart muscle and possibly the patient’s life. Continue reading
Stents, Trials and Studies: What’s in a Word?
Today the editors of the HEART Group Journals, comprising the Journal of the American College of Cardiology and other participating cardiovascular publications, issued a “Statement on Matching Language to the Type of Evidence Used in Describing Outcomes Data.”
Although the title of the article may be a bit yawn-inducing, the editors deserve a kudo or two for attempting to clarify reporting on medical issues. Continue reading
A Stent By Any Other Name Now Has Other Names!
Is this stent necessary? Is this angioplasty inappropriate? Is this cardiologist uncertain if the procedure will help? Ever since the Appropriate Use Criteria for Coronary Revascularization were published, the three category labels of “appropriate,” “uncertain,” and “inappropriate” have confused the profession, press and population at large. The issue of definitions had still not been addressed in the most recent update of the AUC.
So (drumroll, please) yesterday, new categories were approved by the ACC Appropriateness Use Criteria Working Group. The new terminology will be “Appropriate,” “May Be Appropriate”(which replaces “Uncertain”), and “Rarely Appropriate” (which replaces “Inappropriate”). Continue reading
The Question of Angioplasty in the Elderly
We just posted a report on the XIMA Trial which studied stents in octogenarians. The trial compared drug-eluting with bare-metal stents and the results are very interesting: while the trial didn’t find a difference in these two types of stents for the pre-specified composite endpoint of death, heart attack, revascularization, stroke and major bleeding…it did find significantly lower incidence of revascularization and heart attack in those patients who received the drug-eluting Xience stent.
But the real take-away from the XIMA Trial is that stenting and angioplasty in the elderly is safe and effective. Mortality from cardiac causes in this trial was 4% at one year, no matter which stent was used. Continue reading
NEJM: Obama and Romney on the Future of Health Care
Published “online first” today in the New England Journal of Medicine are two articles, authored by the Democratic and Republican presidential nominees, President Barack Obama and former Massachusetts Governor Mitt Romney, describing their health care platforms and their visions for the future of American health care. The editors of NEJM had asked the nominees for these statements which are brief and concise, summing up the two positions in less than 1,300 words each.
President Obama’s statement, titled “Securing the Future of American Health Care,” recaps the highlights of the Affordable Care Act, passed in his first term, and lays out plans for future improvements. Continue reading
Filed under Cost Effectiveness, FDA, Health Insurance, Patients
RSS Feed
